Kinetic of virologic response to pegylated interferon and ribavirin in children with chronic hepatitis c predicts the effect of treatment

Pediatric Infectious Disease Journal

Volumn 35, Issue 12, 2016, Pages 1300-1303

  Indolfi, Giuseppe ^a   Nebbia, Gabriella ^b   Cananzi, Mara ^c   Maccabruni, Anna ^d   Zaramella, Marco ^d   D'Antiga, Lorenzo ^e   Grisotto, Laura ^f   Azzari, Chiara ^f   Resti, Massimo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

^e PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^f UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Children; HCV; SVR predictors; Treatment

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN; VIRUS RNA;

ADOLESCENT; ARTICLE; CHILD; CHRONIC HEPATITIS C; COHORT ANALYSIS; FEMALE; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; ITALIAN (CITIZEN); MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIREMIA; VIROLOGIC RESPONSE; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MULTICENTER STUDY; PRESCHOOL CHILD; VIRUS LOAD;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84987899131     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000001325     Document Type: Article

References (15)

1. Serranti D, Indolfi G, Resti M. New treatments for chronic hepatitis C: an overview for paediatricians. World J Gastroenterol. 2014;20:15965-15974.
2. Thorne C, Indolfi G, Turkova A, et al. Treating hepatitis C virus in children: time for a new paradigm. J Virus Erad. 2015;1:203-205.
3. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965.
4. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
5. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401.
6. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60:392-420.
7. Ghany MG, Strader DB, Thomas DL, et al; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335-1374.
8. Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003;38:645-652.
9. Wirth S, Kelly D, Sokal E, et al. Guidance for clinical trials for children and adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr. 2011;52:233-237.
10. Sokal EM, Bourgois A, Stephenne X, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol. 2010;52:827-831.
11. Wirth S, Ribes-Koninckx C, Calzado MA, et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol. 2010;52:501-507.
12. Domagalski K, Pawłowska M, Tretyn A, et al. Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4. Eur J Clin Microbiol Infect Dis. 2013;32:745-754.
13. Komatsu H, Inui A, Tsunoda T, et al. Association between an IL-28B genetic polymorphism and the efficacy of the response-guided pegylated interferon therapy in children with chronic hepatic C infection. Hepatol Res. 2013;43:327-338.
14. Shaker OG, Nassar YH, Nour ZA, et al. Single-nucleotide polymorphisms of IL-10 and IL-28B as predictors of the response of IFN therapy in HCV genotype 4-infected children. J Pediatr Gastroenterol Nutr. 2013;57:155-160.
15. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139:120-129.e18.